Fused positron emission tomography (PET)/computed tomography (CT) is a recently developed technology that couples the functional information of PET with the anatomic details of CT. Integrated PET/CT scanners produce both PET and contrast material-enhanced CT images of the entire body in one setting. Typically, the amount of fluorine 18 (F-18) fluorodeoxyglucose (FDG) uptake in normal pancreatic parenchyma is insignificant compared with that of the liver. However, both malignant (eg, adenocarcinoma) and benign (eg, acute pancreatitis) pancreatic conditions may demonstrate intense FDG uptake. PET/CT provides an opportunity to depict pancreatic tumors and distant metastases, perform preoperative staging, and monitor response to treatment, and ...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
Pancreatic Cancer (PC) has a poor prognosis, with a 5-year survival rate of only 9%. Even after radi...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
Since the introduction of integrated positron emission tomography-computed tomography (PET/CT), it h...
Background: Pancreatic malignancies encompass a heterogenous group of disorders, with poor prognosis...
Objectives: Fluorodeoxyglucose (FDG)-positron emission tomography/contrast-enhanced computed tomogra...
Objective: To evaluate the role of PET/CT with contrast enhanced CT in diagnosing and staging for pa...
Pancreatic ductal adenocarcinoma is known for its poor prognosis. Since the development of computeri...
The assessment of hepatobiliary and pancreatic tumors is commonly achieved by ultrasound, computed t...
AbstractBackgroundThe role of fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) scannin...
The assessment of hepatobiliary and pancreatic tumors is commonly achieved by ultrasound, computed t...
PURPOSE: 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is an imaging techn...
Endocrine pancreatic tumors (EPTs) are a heterogeneous group of neoplasms with variable clinical and...
Endocrine pancreatic tumors (EPTs) are a heterogeneous group of neoplasms with variable clinical and...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
Pancreatic Cancer (PC) has a poor prognosis, with a 5-year survival rate of only 9%. Even after radi...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
Since the introduction of integrated positron emission tomography-computed tomography (PET/CT), it h...
Background: Pancreatic malignancies encompass a heterogenous group of disorders, with poor prognosis...
Objectives: Fluorodeoxyglucose (FDG)-positron emission tomography/contrast-enhanced computed tomogra...
Objective: To evaluate the role of PET/CT with contrast enhanced CT in diagnosing and staging for pa...
Pancreatic ductal adenocarcinoma is known for its poor prognosis. Since the development of computeri...
The assessment of hepatobiliary and pancreatic tumors is commonly achieved by ultrasound, computed t...
AbstractBackgroundThe role of fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) scannin...
The assessment of hepatobiliary and pancreatic tumors is commonly achieved by ultrasound, computed t...
PURPOSE: 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is an imaging techn...
Endocrine pancreatic tumors (EPTs) are a heterogeneous group of neoplasms with variable clinical and...
Endocrine pancreatic tumors (EPTs) are a heterogeneous group of neoplasms with variable clinical and...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...
Pancreatic Cancer (PC) has a poor prognosis, with a 5-year survival rate of only 9%. Even after radi...
BACKGROUND: Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron...